Category: Article

Authors: Peter Bloomingdale, Tatiana Karelina, Vidya Ramakrishnan, Suruchi Bakshi, Florence Véronneau-Veilleux, Matthew Moye, Kazutaka Sekiguchi, Guy Meno-Tetang, Aparna Mohan, R. Maithreye, Veena A. Thomas, Frank Gibbons, Antonio Cabal, Jean-Marie Bouteiller, Hugo Geerts Age-related central neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, are a rising public health concern and have been plagued by repeated drug … Continued

Authors: Govind Menon, Suruchi Bakshi, J. Krishnan It is well-established that misfolded alpha-synuclein (alpha-syn) is a histopathological marker of Parkinson’s disease. Given this, we focus on key pathways centered around alpha-syn to explore the pathogenesis of Parkinson’s disease. These are …

By Hugo Geerts, PhD, Piet van der Graaf, PharmD, PhD Over the past 20 years, less than a handful of completed Phase III Alzheimer disease (AD) clinical trials have been successful. Despite large investments of capital and research, more than 200 investigational programs have failed or …

Authors: Liming Fang, Emi Akatsu, Phillip Johnston Founded in 2016, Zhejiang Longcharm Biomedicine Technology Co., Ltd. provides one-stop R&D outsourcing services for the Chinese pharmaceutical industry. They can support BA/BE/PK clinical testing and data analysis services that comply with Chinese and American regulatory requirements for both novel and generic drug development programs. In 2023 July, … Continued

Authors: Stephanie H. Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle & Francois-Clement Bidard To assess real-world treatment patterns in patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) who received cyclin-dependent kinase 4/6 (CDK4/6) inhibitors … Continued

By Maximillian Vargas and Caitlin Verrilli As IRA provisions are activated, the law’s impact on biologics and biosimilars will become more apparent. By using both the carrot and the stick, the IRA may finally…

By Clinical Research Team  We spoke with leaders and experts in the Clinical Research community about their predictions…

By Bio-IT World Team  To kick off the New Year, we spoke with leaders and experts in the Bio-IT community about their predictions…

A FRIENDS OF CANCER RESEARCH WHITE PAPER The article explores the complex landscape of determining optimal drug doses in early-phase oncology trials, with a focus on achieving a delicate balance between efficacy and safety. Traditionally centered on the maximum tolerated dose (MTD), contemporary therapies require a paradigm shift towards premarket dose optimization. Guided by Project … Continued